Sucampo Announces Third Quarter 2017 Earnings Call
October 23 2017 - 4:05PM
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global
biopharmaceutical company, today announced that it will host its
third quarter 2017 financial results teleconference and webcast at
8:30 a.m. Eastern on Wednesday, November 1st. The press release
announcing the financial results and operating highlights is
expected to be released before the opening of capital markets that
day.
Individuals interested in accessing the live
audio webcast of the teleconference may do so at
http://www.sucampo.com/investors/events-presentations/ and should
log on 10 to 15 minutes before the teleconference begins to
download any software required. Presentation slides will be
available via the webcast link. A replay of the webcast will also
be available on Sucampo’s website for several days after the live
event. Alternatively, individuals may dial 888-636-8238 (domestic)
or 484-747-6635 (international) and use passcode 97804103. A replay
of the teleconference will be available by dialing 855-859-2056
(domestic) or 404-537-3406 (international), passcode 97804103,
approximately two hours after the teleconference concludes. The
archive of the teleconference will be available for 30 days.
About Sucampo Pharmaceuticals,
Inc.
Sucampo Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and
commercialization of highly specialized medicines. Sucampo
has a late-stage pipeline of product candidates in clinical
development for orphan disease areas, including VTS-270, a
2-hydroxypropyl-beta-cyclodextrin product with a specific
compositional fingerprint that has been granted orphan designation
in the U.S. and Europe and is in a pivotal Phase 2b/3 clinical
trial for the treatment of Niemann-Pick Disease Type C-1, a rare
progressive genetic disorder. VTS-270 also has been granted
breakthrough therapy designation in the U.S. Sucampo has an
exclusive option for the North American rights to CPP1-x/sulindac,
which is in Phase 3 development for the treatment of familial
adenomatous polyposis and has been granted orphan drug designation
in the U.S. The company has two marketed products – AMITIZA and
RESCULA. For more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of
Innovation, are registered trademarks of Sucampo AG. AMITIZA is a
registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow
us on LinkedIn (Sucampo Pharmaceuticals).Twitter
LinkedIn
Contact:Sucampo Pharmaceuticals, Inc.Silvia
TaylorSenior Vice President, Investor Relations and Corporate
Affairs1-240-223-3718staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Apr 2024 to May 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From May 2023 to May 2024